#ASH21 Oral abstract:Ciltacabtagene Autoleucel for Triple-Class Exposed MM:Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study #mmsm 🧵
➡️ash.confex.com/ash/2021/webpr…
🛑some important issues👇
➡️ash.confex.com/ash/2021/webpr…
🛑some important issues👇
#ASH21 #mmsm
➡️Cilta Cel is effective in difficult to ttt pts, this is not the aim of the discussion
➡️In this abstract,authors compared a prospectively matched triple class ref MM pts who received diff ttt vs Cilta cel
➡️ what did they find? 👇 (Cilta Cel better) but wait🛑
➡️Cilta Cel is effective in difficult to ttt pts, this is not the aim of the discussion
➡️In this abstract,authors compared a prospectively matched triple class ref MM pts who received diff ttt vs Cilta cel
➡️ what did they find? 👇 (Cilta Cel better) but wait🛑
➡️Read results 👇
1️⃣countries:only 9% RWCP in US vs. 100% of pts who got Cilta Cel in CARTITUDE-1 were in US (16 Center) ➡️study compared pts across the ocean with diff access to ttt🙈
2️⃣>90 ttt options😅
3️⃣2 of the most frequently used regimens were doublet 🙈Kd (~14%),Pd (11%)
1️⃣countries:only 9% RWCP in US vs. 100% of pts who got Cilta Cel in CARTITUDE-1 were in US (16 Center) ➡️study compared pts across the ocean with diff access to ttt🙈
2️⃣>90 ttt options😅
3️⃣2 of the most frequently used regimens were doublet 🙈Kd (~14%),Pd (11%)
Is it fair to compare “prospectively matched” R/R MM pts with doublet vs. CAR-T across diff countries with diff access to diff therapies?! 🤷♂️
At least does in the US: patient with excellent ECOG, organ function , etc (CAR-T candidate) will def receive a better regimen 😅
At least does in the US: patient with excellent ECOG, organ function , etc (CAR-T candidate) will def receive a better regimen 😅
Few Qs to ask authors at presentation
❓percentage of pts in RW with ASCT (baseline)+who received salvage ASCT?
❓percentage of pts in RW who received triple/Quad+newer agents (bispecific)
❓ sequencing of ttt+details of >90 therapies ,it is imp to see what you are comparing to
❓percentage of pts in RW with ASCT (baseline)+who received salvage ASCT?
❓percentage of pts in RW who received triple/Quad+newer agents (bispecific)
❓ sequencing of ttt+details of >90 therapies ,it is imp to see what you are comparing to
➡️While Cilta Cel is effective(no doubt),IMO this comparison is NOT fair and the results are NOT informative
➡️ appropriate RCT comparison with appropriate control for similar pts/access is the way to go
Tagging for opinions @ManniMD1 @RahulBanerjeeMD @amarkelkar @rajshekharucms
➡️ appropriate RCT comparison with appropriate control for similar pts/access is the way to go
Tagging for opinions @ManniMD1 @RahulBanerjeeMD @amarkelkar @rajshekharucms
• • •
Missing some Tweet in this thread? You can try to
force a refresh
